<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303391</url>
  </required_header>
  <id_info>
    <org_study_id>STU 032017-024</org_study_id>
    <nct_id>NCT03303391</nct_id>
  </id_info>
  <brief_title>Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration</brief_title>
  <acronym>IBPS</acronym>
  <official_title>Using Intradialytic Systolic Blood Pressure Slopes to Guide Ultrafiltration in Hemodialysis Patients: A Validation Study and Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label randomized clinical trial that comparing intradialytic blood
      pressure slope-based ultrafiltration prescriptions to standard care in the chronic fluid
      management of maintenance hemodialysis patients. It also includes a cross sectional component
      evaluating the associations between intradialytic blood pressure slopes ascertained over 2
      week periods with measurements of extracellular water/body weight obtained with
      multifrequency bioimpedance spectroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory Systolic Blood Pressure</measure>
    <time_frame>4 months</time_frame>
    <description>expected reduction of at least 3 mmHg greater reduction for IBPS compared to standard care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extracellular Volume/Body Weight Ratio</measure>
    <time_frame>4 months</time_frame>
    <description>expected reduction of at least 0.025 greater reduction for IBPS compared to standard care</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>ESRD</condition>
  <condition>Extracellular Fluid Alteration</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm of subjects will have all aspects of fluid management and dialysis management managed by the his/her individual nephrologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBPS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will have ultrafiltration prescriptions dictated by a pre-specified protocol that is based on monthly assessment of intradialytic blood pressure slopes obtained over a two week period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intradialytic Blood Pressure Slope Based Ultrafiltration</intervention_name>
    <description>Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments</description>
    <arm_group_label>IBPS Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 18 years

          -  End Stage Renal Disease on Maintenance Hemodialysis

          -  Hypertension defined as systolic blood pressure &gt; 140 mmHg pre-dialysis or &gt;130 mmHg
             post dialysis

        Exclusion Criteria:

          -  Hemodialysis Vintage &lt; 1 month

          -  Pregnancy

          -  Nadir Systolic Blood Pressure &lt; 95 mmHg

          -  Pre or Post dialysis systolic blood pressure &gt; 180 mmHg

          -  Decrease in systolic blood pressure &gt;60 mmHg from pre to post dialysis

          -  Ultrafiltration rate &gt;13 mL/kg/hr

          -  Peridialytic Midodrine Use

          -  Intradialytic Clonidine use

          -  Documented Antihypertensive Medication Non-adherence

        Bioimpedance will not be peformed on patients with

          -  amputated arms or legs

          -  cardiac defibrillator or pacemaker

          -  presence of metal prostheses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Van Buren, MD, MSCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Van Buren, MD, MSCS</last_name>
    <phone>214-645-8293</phone>
    <email>peter.vanburen@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Davita Dialysis</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PETER VAN BUREN</last_name>
      <phone>214-645-8293</phone>
      <email>peter.vanburen@utsouthwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Peter Van Buren</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

